Journal
BLOOD
Volume 113, Issue 2, Pages 291-298Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-04-153239
Keywords
-
Categories
Funding
- Dutch Cancer Society Koningin Wilhelmina Fonds (Amsterdam, The Netherlands)
- National Institutes of Health (Bethesda, MD) [CA118316]
Ask authors/readers for more resources
The past decade has shown a marked increase in the use of high-throughput assays in clinical research into human cancer, including acute myeloid leukemia (AML). In particular, genome-wide gene expression profiling (GEP) using DNA microarrays has been extensively used for improved understanding of the diagnosis, prognosis, and pathobiology of this heterogeneous disease. This review discusses the progress that has been made, places the technologic limitations in perspective, and highlights promising future avenues. (Blood. 2009;113:291-298)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available